Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurofibromatosis Type 2: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Neurofibromatosis Type 2: 3 US clinical trials tracked, none currently recruiting.
Neurofibromatosis Type 2 is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Scott R. Plotkin, MD, PhD, running 1 of these trials.
Enrollment posture brief
Registry condition neurofibromatosis-type-2
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Neurofibromatosis Type 2 has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurofibromatosis Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurofibromatosis Type 2 is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Scott R. Plotkin, MD, PhD
NCT04374305
Doxycycline in Cutaneous Schwannoma (NF2)
Massachusetts Eye and Ear Infirmary
NCT05521048
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
National Cancer Institute (NCI)
NCT01207687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurofibromatosis Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurofibromatosis Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurofibromatosis Type 2 page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Neurofibromatosis Type 2 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Scott R. Plotkin, MD, PhD sponsors the most Neurofibromatosis Type 2 trials on record, review their full trial history before evaluating a specific study. See Scott R. Plotkin, MD, PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurofibromatosis Type 2 condition card totals 3 registered trials; most-linked intervention Doxycycline Injection [Doxy]; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.